What is HC Wainwright's Forecast for MNPR FY2026 Earnings?

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - HC Wainwright increased their FY2026 earnings estimates for Monopar Therapeutics in a report issued on Wednesday, January 22nd. HC Wainwright analyst S. Lee now forecasts that the company will post earnings of $0.70 per share for the year, up from their previous estimate of $0.12. HC Wainwright currently has a "Buy" rating and a $40.00 target price on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics' FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.

MNPR has been the topic of a number of other reports. Piper Sandler started coverage on shares of Monopar Therapeutics in a report on Friday, January 10th. They issued an "overweight" rating and a $72.00 price target on the stock. Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $50.00 price objective on the stock.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock traded up $2.28 during mid-day trading on Friday, hitting $41.60. The company's stock had a trading volume of 113,123 shares, compared to its average volume of 57,897. Monopar Therapeutics has a one year low of $1.54 and a one year high of $41.94. The stock has a market cap of $253.73 million, a PE ratio of -20.88 and a beta of 1.23. The company has a 50 day moving average of $24.19 and a 200-day moving average of $12.34.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09.

Insiders Place Their Bets

In related news, CFO Karthik Radhakrishnan acquired 1,550 shares of the stock in a transaction on Monday, October 28th. The shares were bought at an average price of $16.25 per share, with a total value of $25,187.50. Following the completion of the purchase, the chief financial officer now owns 1,550 shares of the company's stock, valued at approximately $25,187.50. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 34.90% of the stock is currently owned by corporate insiders.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.